Thyroid Nodules: Evaluation and Treatment Approaches

Eleonora Miliordos^*
*Correspondence: Eleonora Miliordos, Department of Medical Sciences, School of Medicine, University of Patras, 26504 Patras, Greece, Email:

Keywords

Thyroid nodules • Evaluation • Fine-needle aspiration biopsy • Ultrasound •Thyroid cancer

Introduction

Thyroid nodules are discrete lesions within the thyroid gland that are often detected during routine physical examinations or imaging studies. While the majority of thyroid nodules are benign, a small percentage can be malignant, necessitating a thorough evaluation to determine the appropriate course of action. The prevalence of thyroid nodules increases with age and is higher in women. Advances in diagnostic techniques have improved the ability to distinguish between benign and malignant nodules, allowing for more targeted and effective treatment strategies. This paper aims to explore the various evaluation methods and treatment approaches for thyroid nodules, emphasizing evidence-based practices to optimize patient care. Thyroid nodules are a common clinical finding, with a prevalence that increases with age, affecting up to 50% of the population over the age of 60 [1]. These nodules are discrete lesions within the thyroid gland that may be discovered incidentally during imaging for other conditions or during routine physical examinations. While the majority of thyroid nodules are benign, a small percentage can be malignant, necessitating careful evaluation and appropriate management. The increasing use of high-resolution ultrasonography has led to a higher detection rate of thyroid nodules, which has amplified the need for effective evaluation and treatment strategies. The management of thyroid nodules involves a combination of clinical assessment, imaging, Fine-Needle Aspiration Biopsy (FNAB), and, in some cases, molecular testing to determine the nature of the nodule and guide treatment decisions. This comprehensive approach aims to identify malignant nodules early while avoiding unnecessary interventions for benign lesions.

Literature Review

The evaluation of thyroid nodules typically begins with a comprehensive clinical assessment, including a detailed patient history and physical examination. Risk factors for malignancy, such as a family history of thyroid cancer, previous radiation exposure, and rapid nodule growth, are important considerations. High-resolution ultrasound is the primary imaging modality used to assess the size, composition, and vascularity of the nodule [2]. Ultrasound features such as micro calcifications, irregular margins, and taller-than-wide shape can suggest malignancy. Fine-needle Aspiration Biopsy (FNAB) is a crucial diagnostic tool for obtaining cytological samples from the nodule, providing valuable information to guide management decisions. The Bethesda System for Reporting Thyroid Cytopathology standardizes FNAB results, categorizing them into six diagnostic groups with corresponding management recommendations. Active surveillance is often appropriate for benign nodules or those with low suspicion for malignancy, with regular follow-up ultrasounds to monitor for any changes. The evaluation of thyroid nodules begins with a thorough clinical history and physical examination.

Important factors to consider include the patient’s age, gender, radiation exposure history, family history of thyroid cancer, and symptoms such as dysphagia, dysphonia, or rapid nodule growth, which may raise suspicion for malignancy. Physical examination should assess the size, consistency, and mobility of the nodule, as well as the presence of cervical lymphadenopathy. Following the clinical assessment, imaging studies, particularly high-resolution ultrasonography, are critical in the evaluation of thyroid nodules [3]. Ultrasonography provides detailed information about the nodule’s size, composition (solid, cystic, or mixed), echogenicity, margins, and the presence of microcalcifications, which are features associated with a higher risk of malignancy. The American Thyroid Association (ATA) and other professional organizations have developed ultrasound-based risk stratification systems to categorize nodules and guide further management. Nodules with suspicious ultrasound features typically warrant further evaluation with fine-needle aspiration biopsy (FNAB). FNAB is a minimally invasive procedure that involves using a thin needle to obtain a sample of cells from the thyroid nodule for cytological examination. This procedure is highly accurate and helps to differentiate benign from malignant nodules. The Bethesda System for Reporting Thyroid Cytopathology classifies FNAB results into six categories, ranging from benign to malignant, with indeterminate categories such as atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS), which can pose a diagnostic challenge. In cases where FNAB results are indeterminate, molecular testing of the biopsy sample can provide additional diagnostic information.

Molecular markers, such as mutations, have been identified in thyroid cancer and can help predict the likelihood of malignancy in indeterminate nodules [4]. These tests can improve diagnostic accuracy and guide clinical decision-making. The treatment of thyroid nodules depends on the nature of the nodule and the patient’s clinical presentation. Benign nodules, which constitute the majority, can often be managed conservatively with periodic monitoring using ultrasound to assess for changes in size or characteristics. If a benign nodule causes compressive symptoms or cosmetic concerns, surgical intervention may be considered. Malignant nodules, on the other hand, require more aggressive treatment. The primary treatment for thyroid cancer is surgical resection, which can range from lobectomy (removal of one lobe of the thyroid) to total thyroidectomy (removal of the entire thyroid gland) depending on the type and extent of the cancer. Following surgery, radioactive iodine ablation may be used to eliminate any remaining thyroid tissue or metastatic disease. Thyroid hormone suppression therapy is also commonly employed to reduce the risk of cancer recurrence by suppressing TSH, which can stimulate thyroid cancer cell growth.

Treatment approaches for thyroid nodules vary based on the nodule's characteristics and the patient's overall health. Benign nodules may be managed with active surveillance, involving periodic ultrasound monitoring to detect any changes. Suspicious or malignant nodules often necessitate surgical intervention, ranging from lobectomy to total thyroidectomy, depending on the extent of the disease. Minimally invasive techniques, such as radiofrequency ablation, have emerged as alternative treatments for selected patients. The choice of treatment should be individualized, considering the potential benefits and risks, as well as the patient's preferences.

Discussion

Thyroid nodules present a diagnostic and therapeutic challenge due to their diverse nature and potential for malignancy. The initial evaluation using clinical assessment and high-resolution ultrasound is crucial for risk stratification. Features such as nodule size, echogenicity, and the presence of suspicious ultrasound characteristics help determine the likelihood of malignancy and guide further diagnostic steps. Fine-needle aspiration biopsy (FNAB) remains the gold standard for cytological evaluation, providing essential information to classify nodules according to the Bethesda System. This classification aids in determining the management approach, whether it be active surveillance, repeat FNAB, molecular testing, or surgical intervention [5]. This approach minimizes unnecessary surgeries and associated complications. For nodules with indeterminate or suspicious cytology, molecular testing can offer additional information to guide decision-making. Genetic markers and molecular profiles can help distinguish benign from malignant nodules, reducing diagnostic uncertainty and aiding in personalized treatment planning. Surgical intervention is the primary treatment for nodules with confirmed or highly suspected malignancy.

The extent of surgery, whether lobectomy or total thyroidectomy, depends on factors such as the size of the nodule, the presence of multifocal disease, and patient-specific considerations. Minimally invasive procedures like radiofrequency ablation have gained popularity for treating benign nodules and small, low-risk cancers, offering a less invasive alternative with shorter recovery times. The management of thyroid nodules requires a multidisciplinary approach involving endocrinologists, radiologists, pathologists, and surgeons. Patient education and involvement in decision-making are crucial, as treatment choices can significantly impact quality of life. Advances in diagnostic techniques, such as high-resolution ultrasound and molecular testing, continue to enhance our ability to accurately evaluate and manage thyroid nodules, improving patient outcomes. The management of thyroid nodules presents several challenges, particularly in the context of indeterminate cytology and the potential for overtreatment. One of the main challenges in thyroid nodule evaluation is the management of indeterminate FNAB results. While the introduction of molecular testing has improved diagnostic accuracy, it is not without limitations and may not be universally available or cost-effective.

The choice between conservative management and surgical intervention must be carefully weighed, considering the patient’s risk factors, preferences, and the potential impact on quality of life. For instance, surgery carries risks such as damage to the recurrent laryngeal nerve and hyperparathyroidism, which must be balanced against the benefits of definitive diagnosis and treatment. Advances in minimally invasive techniques, such as thermal ablation, have emerged as potential alternatives to surgery for select patients with benign thyroid nodules. These techniques, including radiofrequency ablation (RFA) and laser ablation, offer the advantages of reduced morbidity, shorter recovery times, and preservation of thyroid function. However, long-term data on the efficacy and safety of these approaches are still being evaluated. Furthermore, the role of active surveillance in the management of small, low-risk papillary thyroid microcarcinomas (PTMCs) is gaining acceptance [6]. Studies have shown that carefully selected patients with PTMCs can be managed with active surveillance, with low rates of disease progression and excellent long-term outcomes. This approach aims to reduce overtreatment and its associated complications, particularly in populations with a high prevalence of indolent thyroid cancers.

Conclusion

Thyroid nodules are common and often benign, but their potential for malignancy necessitates a thorough and systematic evaluation. Clinical assessment, high-resolution ultrasound, and fine-needle aspiration biopsy are key components of the diagnostic process, providing essential information for risk stratification and management planning. Treatment approaches range from active surveillance for benign nodules to surgical intervention for suspicious or malignant ones, with emerging minimally invasive techniques offering additional options. A multidisciplinary approach and patient-centered care are essential for optimizing outcomes in the management of thyroid nodules. On-going research and advancements in diagnostic and therapeutic technologies promise to further improve the evaluation and treatment of thyroid nodules, ensuring better health outcomes for patients. In conclusion, the evaluation and treatment of thyroid nodules have evolved significantly with advancements in imaging, cytology, molecular testing, and minimally invasive techniques. A multidisciplinary approach that integrates clinical assessment, advanced imaging, FNAB, and molecular diagnostics is essential for accurate diagnosis and effective management.

While the majority of thyroid nodules are benign and can be managed conservatively, the identification and treatment of malignant nodules require careful consideration to optimize patient outcomes and minimize complications. The emerging role of active surveillance for low-risk thyroid cancers and the development of minimally invasive treatments represent important strides in reducing overtreatment and enhancing patient quality of life. On-going research and innovation in this field are crucial to further refine diagnostic and therapeutic strategies, ensuring that patients receive the most appropriate and personalized care for their thyroid nodules.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Rallison, Marvin L., Brown M. Dobyns, F. Raymond Keating and Joseph E. Rall, et al. "Thyroid nodularity in children." Jama 233 (1975): 1069-1072.

Google Scholar, Crossref, Indexed at

2. Rallison, Marvin L., Brown M. Dobyns, A. Wayne Meikle and Mary Bishop, et al. "Natural history of thyroid abnormalities: Prevalence, incidence, and regression of thyroid diseases in adolescents and young adults." Am J Med 91 (1991): 363-370.

Google Scholar, Crossref, Indexed at

3. Fowler, C. L., W. J. Pokorny and F. J. Harberg. "Thyroid nodules in children: Current profile of a changing disease." South Med J 82 (1989): 1472-1478.

Google Scholar, Crossref, Indexed at

4. Gupta, Anjuli, Samantha Ly, Luciana A. Castroneves and Mary C. Frates, et al. "A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults." J Clin Endocrinol Metab 98 (2013): 3238-3245.

Google Scholar, Crossref, Indexed at

5. Corrias, Andrea and Alessandro Mussa. "Thyroid nodules in pediatrics: Which ones can be left alone, which ones must be investigated, when and how." J Clin Res Pediatr Endocrinol 5 (2013): 57.

Google Scholar, Crossref, Indexed at

6. Jonklaas, Jacqueline, Nicholas J. Sarlis, Danielle Litofsky and Kenneth B. Ain, et al. "Outcomes of patients with differentiated thyroid carcinoma following initial therapy." Thyroid 16 (2006): 1229-1242.

Google Scholar, Crossref, Indexed at